Klemens Rappersberger
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 07, 2024
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.
Journal: Communications medicine
Published: May 13, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Journal: Molecular cancer
Published: January 02, 2024
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Journal: Melanoma research
Published: December 13, 2023
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Journal: Research square
Published: December 11, 2023
Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells.
Journal: Nature cancer
Published: September 18, 2023
Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics.
Journal: The Journal of investigative dermatology
Published: August 25, 2023
Automated classification of hidradenitis suppurativa disease severity by convolutional neural network analyses using calibrated clinical images.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 14, 2023
Oral fusidic acid for the treatment of mild-to-moderate hidradenitis suppurativa.
Journal: International journal of dermatology
Published: May 23, 2023
Melanoma risk during immunomodulating treatment.
Journal: Melanoma research
Published: August 22, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 09, 2022
Last Updated: 09/26/2026